At the beginning of January, Metsera reported preliminary Phase 2a data showing the drug led to dose-dependent weight loss. At the high dose, the average placebo-adjusted weight loss from the ...

This summary highlights significant health news, covering topics such as HIV treatment during U.S. aid pauses, Pfizer's diversity program legal settlement, AstraZeneca's halted UK investment, data ...

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Cystic fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

MET-097i achieved up to 11.3% mean placebo-adjusted weight loss at 12 weeks and exhibited a 380-hour (nearly 16-day) half-life and good tolerability. Metsera said the drug's profile is at least as ...

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint bookrunners for the offering.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...